Delivery Order SPE2DB20D3101-SPE2DB25FRSA8
- Not listed
- The Defense Logistics Agency awarded a $3,819.87 delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,182.88 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Valsartan-HCZ 160-25 mg tablets in a quantity of 90 units. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,049.47 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed price delivery order represents a non-set-aside competitive award for pharmaceutical products to support federal medical procurement needs. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,362.54 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on August 18, 2025, with completion expected by August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open contracting vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units, with a contract ceiling value of $11,676.65. This is a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets in a quantity of 90 units, with a contract value of $8,635.00. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025....
- The Defense Logistics Agency awarded a delivery order valued at $8,139.90 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order is non-set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The order represents a single transaction under AmerisourceBergen Drug Corp's existing contract...
- The Defense Logistics Agency awarded a delivery order valued at $5,582.42 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This non-competitive delivery order utilizes firm fixed pricing and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
- The Defense Logistics Agency awarded a delivery order valued at $1,067.90 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count packaging). The contract was awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, utilizing firm fixed-price terms with no set-aside designation. Performance will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) with a ceiling value of $16,944.57. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 12, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRSA8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units, with a ceiling value of $3,305.82. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 8, 2025. The award was made to AmerisourceBergen Drug Corp at its Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen Drug Corp fulfills critical supply requirements for military and veteran healthcare systems through this comprehensive global pharmaceutical support vehicle. The company's contract portfolio with DLA demonstrates its capability to deliver a wide spectrum of pharmaceutical products, including generic and brand-name medications across multiple therapeutic domains, supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/7/25 |